Cross-presentation, dendritic cells, tolerance and immunity - PubMed (original) (raw)
Review
Cross-presentation, dendritic cells, tolerance and immunity
W R Heath et al. Annu Rev Immunol. 2001.
Abstract
This review examines the role of cross-presentation in tolerance and immunity. We discuss (a) the antigenic requirements for cross-presentation, (b) the phenotype of the antigen presenting cell (APC), (c) the cellular interactions and molecular signals involved in cross-priming, and (d) the factors that direct the immune system toward tolerance or immunity. A large part of this review is dedicated to summarizing our current knowledge of the cross-presenting APC.
Similar articles
- Dendritic cells in rheumatoid arthritis: Which subset should be used as a tool to induce tolerance?
Lebre MC, Tak PP. Lebre MC, et al. Hum Immunol. 2009 May;70(5):321-4. doi: 10.1016/j.humimm.2009.02.006. Epub 2009 Feb 21. Hum Immunol. 2009. PMID: 19236901 Review. - High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro.
George TC, Bilsborough J, Viney JL, Norment AM. George TC, et al. Eur J Immunol. 2003 Feb;33(2):502-11. doi: 10.1002/immu.200310026. Eur J Immunol. 2003. PMID: 12645949 - Balancing tolerance and immunity: the role of dendritic cell and T cell subsets.
Shklovskaya E, Fazekas de St Groth B. Shklovskaya E, et al. Methods Mol Biol. 2007;380:25-46. doi: 10.1007/978-1-59745-395-0_2. Methods Mol Biol. 2007. PMID: 17876085 Review. - Direct antigen presentation by DC shapes the functional CD8(+) T-cell repertoire against the nuclear self-antigen La-SSB.
Keech CL, Pang KC, McCluskey J, Chen W. Keech CL, et al. Eur J Immunol. 2010 Feb;40(2):330-8. doi: 10.1002/eji.200939522. Eur J Immunol. 2010. PMID: 19950171 - On cross-priming of MHC class I-specific CTL: rule or exception?
Zinkernagel RM. Zinkernagel RM. Eur J Immunol. 2002 Sep;32(9):2385-92. doi: 10.1002/1521-4141(200209)32:9<2385::AID-IMMU2385>3.0.CO;2-V. Eur J Immunol. 2002. PMID: 12207322 Review. No abstract available.
Cited by
- Simultaneous enhancement of cellular and humoral immunity by the lymph node-targeted cholesterolized TLR7 agonist liposomes.
Wan D, Bai Z, Zhang Y, Chen L, Que H, Lan T, Hong W, Huang J, He C, Wei Y, Pu Q, Wei X. Wan D, et al. Acta Pharm Sin B. 2024 Oct;14(10):4577-4590. doi: 10.1016/j.apsb.2024.06.006. Epub 2024 Sep 4. Acta Pharm Sin B. 2024. PMID: 39525596 Free PMC article. - Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors.
Chen S, Lei J, Mou H, Zhang W, Jin L, Lu S, Yinwang E, Xue Y, Shao Z, Chen T, Wang F, Zhao S, Chai X, Wang Z, Zhang J, Zhang Z, Ye Z, Li B. Chen S, et al. Front Immunol. 2024 Feb 23;15:1335366. doi: 10.3389/fimmu.2024.1335366. eCollection 2024. Front Immunol. 2024. PMID: 38464516 Free PMC article. Review. - Targeting lymph node delivery with nanovaccines for cancer immunotherapy: recent advances and future directions.
Li Y, Li S, Jiang Z, Tan K, Meng Y, Zhang D, Ma X. Li Y, et al. J Nanobiotechnology. 2023 Jul 7;21(1):212. doi: 10.1186/s12951-023-01977-1. J Nanobiotechnology. 2023. PMID: 37415161 Free PMC article. Review. - Tolerogenic dendritic cells in type 1 diabetes: no longer a concept.
Giannoukakis N. Giannoukakis N. Front Immunol. 2023 Jun 14;14:1212641. doi: 10.3389/fimmu.2023.1212641. eCollection 2023. Front Immunol. 2023. PMID: 37388741 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources